Urogen Pharma LtdNASDAQ:URGN
- LAST PRICE13.3300
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots12.8000/ 1
- Ask / Lots14.4500/ 1
- Open / Previous Close13.0200 / 13.3300
- Day Range
- 52 Week Range
- Volume121,785
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | URGN |
|---|---|---|
| 09:32 ET | 1074 | 13.09 |
| 09:35 ET | 651 | 13.195 |
| 09:37 ET | 100 | 13.32 |
| 09:39 ET | 100 | 13.23 |
| 09:42 ET | 500 | 13.315 |
| 09:46 ET | 300 | 13.16 |
| 09:48 ET | 300 | 13.16 |
| 09:53 ET | 755 | 13.18 |
| 10:02 ET | 100 | 13.135 |
| 10:08 ET | 1193 | 13.07 |
| 10:09 ET | 113 | 13.035 |
| 10:11 ET | 100 | 13.03 |
| 10:15 ET | 1083 | 13.105 |
| 10:18 ET | 1924 | 12.99 |
| 10:22 ET | 2400 | 12.93 |
| 10:26 ET | 210 | 12.93 |
| 10:27 ET | 800 | 13 |
| 10:29 ET | 100 | 13.06 |
| 10:38 ET | 300 | 13.0432 |
| 10:40 ET | 1700 | 13.15 |
| 10:42 ET | 1916 | 13.2725 |
| 10:45 ET | 1480 | 13.28 |
| 10:51 ET | 1511 | 13.25 |
| 10:56 ET | 100 | 13.25 |
| 10:58 ET | 100 | 13.19 |
| 11:02 ET | 100 | 13.185 |
| 11:05 ET | 200 | 13.24 |
| 11:12 ET | 551 | 13.24 |
| 11:18 ET | 344 | 13.21 |
| 11:21 ET | 100 | 13.18 |
| 11:25 ET | 200 | 13.18 |
| 11:34 ET | 666 | 13.18 |
| 11:36 ET | 900 | 13.2 |
| 11:38 ET | 500 | 13.18 |
| 11:39 ET | 200 | 13.11 |
| 11:41 ET | 100 | 13.09 |
| 11:57 ET | 100 | 13.13 |
| 12:01 ET | 100 | 13.13 |
| 12:08 ET | 100 | 13.13 |
| 12:12 ET | 400 | 13.15 |
| 12:19 ET | 100 | 13.15 |
| 12:21 ET | 500 | 13.15 |
| 12:28 ET | 100 | 13.17 |
| 12:30 ET | 200 | 13.19 |
| 12:33 ET | 300 | 13.2 |
| 12:35 ET | 300 | 13.24 |
| 12:37 ET | 300 | 13.17 |
| 12:39 ET | 100 | 13.17 |
| 12:50 ET | 400 | 13.23 |
| 12:51 ET | 100 | 13.21 |
| 12:53 ET | 766 | 13.24 |
| 12:55 ET | 898 | 13.2 |
| 01:06 ET | 200 | 13.23 |
| 01:13 ET | 200 | 13.25 |
| 01:15 ET | 100 | 13.24 |
| 01:24 ET | 446 | 13.26 |
| 01:26 ET | 310 | 13.25 |
| 01:27 ET | 200 | 13.19 |
| 01:31 ET | 300 | 13.22 |
| 01:36 ET | 300 | 13.24 |
| 01:45 ET | 100 | 13.23 |
| 01:47 ET | 100 | 13.25 |
| 01:49 ET | 100 | 13.27 |
| 01:51 ET | 1100 | 13.26 |
| 01:56 ET | 330 | 13.24 |
| 02:03 ET | 101 | 13.21 |
| 02:05 ET | 100 | 13.18 |
| 02:07 ET | 100 | 13.17 |
| 02:09 ET | 100 | 13.2 |
| 02:12 ET | 400 | 13.2 |
| 02:16 ET | 100 | 13.25 |
| 02:25 ET | 200 | 13.215 |
| 02:27 ET | 161 | 13.21 |
| 02:30 ET | 100 | 13.21 |
| 02:32 ET | 528 | 13.24 |
| 02:39 ET | 471 | 13.24 |
| 02:43 ET | 100 | 13.26 |
| 02:45 ET | 600 | 13.28 |
| 02:52 ET | 200 | 13.27 |
| 02:57 ET | 250 | 13.3071 |
| 03:01 ET | 6169 | 13.2 |
| 03:03 ET | 639 | 13.19 |
| 03:08 ET | 829 | 13.22 |
| 03:10 ET | 100 | 13.2 |
| 03:14 ET | 300 | 13.191 |
| 03:15 ET | 800 | 13.2175 |
| 03:17 ET | 300 | 13.15 |
| 03:19 ET | 100 | 13.15 |
| 03:21 ET | 300 | 13.19 |
| 03:24 ET | 300 | 13.19 |
| 03:28 ET | 700 | 13.225 |
| 03:30 ET | 100 | 13.25 |
| 03:32 ET | 100 | 13.225 |
| 03:35 ET | 460 | 13.2 |
| 03:37 ET | 706 | 13.25 |
| 03:39 ET | 100 | 13.24 |
| 03:42 ET | 100 | 13.28 |
| 03:44 ET | 200 | 13.3 |
| 03:46 ET | 457 | 13.329 |
| 03:48 ET | 400 | 13.31 |
| 03:50 ET | 430 | 13.305 |
| 03:51 ET | 600 | 13.285 |
| 03:53 ET | 600 | 13.26 |
| 03:55 ET | 900 | 13.3 |
| 03:57 ET | 400 | 13.281 |
| 04:00 ET | 19689 | 13.33 |
Nov 15, 2023
DJ UroGen Pharma Is Maintained at Outperform by Oppenheimer, from 1:33PM ET on Wednesday Nov 15, 2023 by Dow Jones
1:33PM ET on Wednesday Nov 15, 2023 by Dow Jones
Nov 14, 2023
UroGen Pharma Reports Third Quarter 2023 Financial Results, from 8:00AM ET on Tuesday Nov 14, 2023 by Dow Jones
8:00AM ET on Tuesday Nov 14, 2023 by Dow Jones*DJ UroGen Pharma 3Q Loss/Shr 68c >URGN, from 8:00AM ET on Tuesday Nov 14, 2023 by Dow Jones
8:00AM ET on Tuesday Nov 14, 2023 by Dow Jones
Nov 13, 2023
UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology, from 8:00AM ET on Monday Nov 13, 2023 by Dow Jones
8:00AM ET on Monday Nov 13, 2023 by Dow Jones
Nov 7, 2023
Press Release: UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023, from 8:09AM ET on Tuesday Nov 07, 2023 by Dow Jones
8:09AM ET on Tuesday Nov 07, 2023 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Urogen Pharma Ltd | 402.2M | -3.1x | --- |
Y-mAbs Therapeutics Inc | 268.7M | -14.3x | --- |
OmniAb Inc | 534.7M | -15.7x | --- |
Lyell Immunopharma Inc | 481.1M | -2.5x | --- |
Voyager Therapeutics Inc | 334.8M | 6.0x | --- |
Arbutus Biopharma Corp | 340.4M | -4.4x | --- |
Company Information
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Contact Information
- Headquarters
- 9 Ha'ta'asiya StRA'ANANA, Israel 4365007
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Arie Belldegrun
- President, Chief Executive Officer, Director
- Elizabeth Barrett
- Chief Financial Officer
- Dong Kim
- Chief Compliance Officer, General Counsel, Corporate Secretary
- Jason Smith
- Chief Medical Officer
- Mark Schoenberg
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $402.2M |
|---|---|
Revenue (TTM) | $77.3M |
Shares Outstanding | 30.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.99 |
EPS | $-4.25 |
Book Value | $-3.86 |
P/E Ratio | -3.1x |
Price/Sales (TTM) | 5.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -92.15% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
